AU2014352629B2 - Withanolides useful for the treatment of neurodegenerative diseases - Google Patents

Withanolides useful for the treatment of neurodegenerative diseases Download PDF

Info

Publication number
AU2014352629B2
AU2014352629B2 AU2014352629A AU2014352629A AU2014352629B2 AU 2014352629 B2 AU2014352629 B2 AU 2014352629B2 AU 2014352629 A AU2014352629 A AU 2014352629A AU 2014352629 A AU2014352629 A AU 2014352629A AU 2014352629 B2 AU2014352629 B2 AU 2014352629B2
Authority
AU
Australia
Prior art keywords
compound
patient
preventing
treating
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014352629A
Other languages
English (en)
Other versions
AU2014352629A1 (en
Inventor
Agnes H. Chan
Jean-Pierre Julien
Anthony A. Shaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Laval
Arna Therapeutics Inc
Original Assignee
Universite Laval
Imstar Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Laval, Imstar Therapeutics Inc filed Critical Universite Laval
Publication of AU2014352629A1 publication Critical patent/AU2014352629A1/en
Application granted granted Critical
Publication of AU2014352629B2 publication Critical patent/AU2014352629B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2014352629A 2013-11-25 2014-11-25 Withanolides useful for the treatment of neurodegenerative diseases Ceased AU2014352629B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361908455P 2013-11-25 2013-11-25
US61/908,455 2013-11-25
PCT/US2014/067436 WO2015077780A1 (en) 2013-11-25 2014-11-25 Withanolides useful for the treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
AU2014352629A1 AU2014352629A1 (en) 2016-05-26
AU2014352629B2 true AU2014352629B2 (en) 2019-03-28

Family

ID=52023694

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014352629A Ceased AU2014352629B2 (en) 2013-11-25 2014-11-25 Withanolides useful for the treatment of neurodegenerative diseases

Country Status (14)

Country Link
US (1) US10351590B2 (enExample)
EP (1) EP3074414B1 (enExample)
JP (1) JP6517833B2 (enExample)
KR (1) KR20160137945A (enExample)
CN (1) CN105940010B (enExample)
AU (1) AU2014352629B2 (enExample)
BR (1) BR112016012002A2 (enExample)
CA (1) CA2931064C (enExample)
ES (1) ES2728870T3 (enExample)
MX (1) MX364528B (enExample)
PL (1) PL3074414T3 (enExample)
TR (1) TR201905218T4 (enExample)
WO (1) WO2015077780A1 (enExample)
ZA (1) ZA201603117B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3723859B1 (en) * 2017-12-11 2023-08-30 Ethnodyne Compounds for treating neurodegenerative disorders
WO2019116069A1 (en) * 2017-12-11 2019-06-20 Ethnodyne Compounds for treating neurodegenerative disorders
EP3724207A1 (en) * 2017-12-11 2020-10-21 Ethnodyne Compounds for treating neurodegenerative disorders
CN111377994A (zh) * 2018-12-28 2020-07-07 南开大学 七种来源于灯笼果的醉茄内酯类化合物及其制备方法和用途
CN116063373B (zh) * 2023-02-14 2025-04-15 广西医科大学 天然产物27-Deoxywithaferin A的制备方法
TW202521103A (zh) * 2023-10-03 2025-06-01 美商恩維達醫療公司 醉茄素a（withaferin a）類似物及使用彼之治療方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120196815A1 (en) * 2011-02-01 2012-08-02 Kansas University Center for Technology Commercialization Withanolide Isolated from Physalis longifolia and Analogs and Methods of Use Thereof
WO2012174666A1 (en) * 2011-06-22 2012-12-27 UNIVERSITé LAVAL Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110230551A1 (en) * 2008-09-15 2011-09-22 Leslie Gunatilaka Withaferin a analogs and uses thereof
WO2010053655A2 (en) * 2008-11-07 2010-05-14 University Of Kansas Therapeutic methods with withaferin a and analogs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120196815A1 (en) * 2011-02-01 2012-08-02 Kansas University Center for Technology Commercialization Withanolide Isolated from Physalis longifolia and Analogs and Methods of Use Thereof
WO2012174666A1 (en) * 2011-06-22 2012-12-27 UNIVERSITé LAVAL Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FUSKA J ET AL, "Microbial transformations of natural antitumor agents. 23. conversion of withaferin-A to 12beta- and 15beta-hydroxy derivatives of withaferin-A", STEROIDS, 1982, vol. 40, no. 2, pages 157 - 169, (1982-08-01) *
LLANOS GABRIEL G ET AL, "Withaferin A-related steroids fromWithania aristataexhibit potent antiproliferative activity by inducing apoptosis in human tumor cells", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, (2012), vol. 54, pages 499 - 511 *
YOKOTA YASUNO ET AL, "Development of withaferin A analogs as probes of angiogenesis", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (2006), vol. 16, no. 10, doi:10.1016/J.BMCL.2006.02.039, ISSN 0960-894X, pages 2603 - 2607 *

Also Published As

Publication number Publication date
CA2931064A1 (en) 2015-05-28
CA2931064C (en) 2022-10-18
JP6517833B2 (ja) 2019-05-22
CN105940010A (zh) 2016-09-14
US20170022247A1 (en) 2017-01-26
AU2014352629A1 (en) 2016-05-26
WO2015077780A1 (en) 2015-05-28
ES2728870T3 (es) 2019-10-29
TR201905218T4 (tr) 2019-05-21
MX2016006544A (es) 2016-12-12
EP3074414A1 (en) 2016-10-05
BR112016012002A2 (pt) 2017-09-19
PL3074414T3 (pl) 2019-12-31
JP2016537432A (ja) 2016-12-01
KR20160137945A (ko) 2016-12-02
MX364528B (es) 2019-04-30
CN105940010B (zh) 2018-03-30
US10351590B2 (en) 2019-07-16
ZA201603117B (en) 2020-05-27
EP3074414B1 (en) 2019-01-09

Similar Documents

Publication Publication Date Title
AU2014352629B2 (en) Withanolides useful for the treatment of neurodegenerative diseases
CN106103452B (zh) 皮质抑素类似物及其合成和用途
US10857163B1 (en) Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
CA3218620A1 (en) Nmda receptor antagonist and use thereof
KR20100045507A (ko) 글루타메이트성 시냅스 반응을 향상시키기 위한 비시클릭 아미드
EP1601363A2 (fr) Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives
IL291835A (en) Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof
RU2672569C2 (ru) Новое производное оксима хромона и его использование в качестве аллостерического модулятора метаботропных рецепторов глутамата
US11472832B2 (en) Withanolides useful for the treatment of neurodegenerative diseases
WO2017035733A1 (zh) 美金刚与牛蒡子苷元的缀合物及其组合物和用途
EP4587418A1 (en) Compounds for the treatment of neuromuscular disorders
JP7295145B2 (ja) 神経変性疾患を治療するための医薬及びその使用
KR102721799B1 (ko) 신규한 카나비디올 유도체, 이의 제조 방법 및 이를 포함하는 파킨슨병의 예방 또는 치료용 조성물
JP7382944B2 (ja) 神経変性疾患を予防・治療するための新規な化合物及びその応用
EP2682381A2 (en) Spirocyclic cyclopropanoic amino acids - analogues of gamma-aminobutyric acid, with limited conformational mobility, and drugs on the basis thereof
US20190083422A1 (en) Sense-33 compositions and methods thereof for enhancing the expression and/or activity of nicotinic acetylcholine receptors
Gao The development and evaluation of multi-target-directed ligands as cholinergic and amyloid β aggregation inhibitors for Alzheimer's disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired